Provided by Tiger Trade Technology Pte. Ltd.

REMEGEN

78.900
-1.000-1.25%
Volume:3.17M
Turnover:250.29M
Market Cap:44.47B
PE:52.43
High:80.800
Open:79.800
Low:77.250
Close:79.900
52wk High:126.600
52wk Low:63.300
Shares:563.61M
HK Float Shares:208.58M
Volume Ratio:0.85
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.505
ROE:45.33%
ROA:3.38%
PB:9.70
PE(LYR):52.43
PS:11.27

Loading ...

Junshi Biosciences Gets Nod for New Indication for Toripalimab; Shares Down 4%

MT Newswires Live
·
May 22

Movement Alert|RemeGen Rises 3.55% in Regular Trading, Biotech Sector Rally and Strong Q1 Earnings Drive Rebound

Market Focus
·
May 21

RemeGen Allocates Additional RMB50.00 Million to HTSC Wealth Management Products, Raising Total Deployment to RMB538.00 Million

Bulletin Express
·
May 20

RemeGen Plans Board Transition, 20% Share Issuance Mandate, and Redirects IPO Proceeds Amid 2025 Profit Turnaround

Bulletin Express
·
May 20

REMEGEN issues supplemental disclosure after delayed reporting of seven wealth-management product purchases

Bulletin Express
·
May 19

REMEGEN Allocates Additional 35 Million Yuan to Huatai Securities Wealth Management Products

Stock News
·
May 19

RemeGen Invests in Wealth Management Products

MT Newswires Live
·
May 15

REMEGEN Allocates Idle Capital to Huatai Securities Financial Products

Stock News
·
May 15

RemeGen Allocates RMB 453.00 Million of Idle Cash to Low-to-Medium-Risk Wealth Management Products at Huatai Securities

Bulletin Express
·
May 15

RemeGen Allocates US$70.00 Million of Idle Funds to OCBC “Zeng Li” Structured Deposit

Bulletin Express
·
May 14

RemeGen Invests $70 Million in Financial Product from OCBC

Stock News
·
May 14

RemeGen Announces Acquisition of 1.43 Billion Yuan in Bank Wealth Management Products

Stock News
·
May 13

HK Movers | Biotech Stocks Jump. InnoGen up over 44%; Clover Bio up over 11%; Junshi Bio up 9%; Laekna up 8%; Asymchem up over 3%; Tigermed up 2%

Tiger Newspress
·
May 11

Stock Track | REMEGEN Plummets 5.12% Intraday on Lock-up Expiry Fears, Weak Earnings, and Sector Weakness

Stock Track
·
May 11

Stock Track | REMEGEN Plummets 6.51% Intraday on Sharp Q1 Profit Decline and Biotech Sector Weakness

Stock Track
·
May 04

RemeGen Q1 Profit Of ¥328m Revives Bullish Narratives On Biotech Turnaround

Simply Wall St.
·
Apr 29

RemeGen Swings to Profit in Q1 2026

MT Newswires Live
·
Apr 29

REMEGEN Turns Profitable in Q1 2026 on 24.8% Sales Growth and Sharply Lower R&D Spend

Bulletin Express
·
Apr 28

RemeGen 2025 ESG Report: Energy Intensity Cut by 49%, R&D Investment Reaches RMB1.22 Billion

Bulletin Express
·
Apr 28

荣昌生物2025年实现业绩显著扭转 净利达7.10亿元 营收同比增长89.5%

Bulletin Express
·
Apr 28